Search Patents
  • Patent number: 10280199
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: May 7, 2019
    Assignee: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim
  • Publication number: 20060286124
    Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus.
    Type: Application
    Filed: June 30, 2005
    Publication date: December 21, 2006
    Applicant: ID Biomedical Corporation of Quebec
    Inventors: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones
  • Publication number: 20210393769
    Abstract: An immunogenic composition effective for eliciting an immune response against cells that present coronavirus S protein and/or coronavirus M protein derived antigens on a virus-like-particle (VLP) system. In a method embodiment, the antigen presenting VLP is administered to a mammal, such as a human, to elicit an immune response against coronavirus S protein and/or coronavirus M protein. A preferred method embodiment may include at least one additional dose of immunogenic composition to enhance the immune response effectiveness of the coronavirus vaccine.
    Type: Application
    Filed: June 8, 2021
    Publication date: December 23, 2021
    Inventor: Davinder Gill
  • Publication number: 20220031682
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Inventors: Dror Ben-Asher, Reza Fathi
  • Publication number: 20240002935
    Abstract: The present invention is directed to management of coronavirus exposure and/or infection by analyzing a patients 21 SNPs of the patients AGT, renin, AT1R, ACE, ADRB1 and ACE2 genes arnd use of the analysis to determine which pharmaceutical compound(s) associated with treatment of the RAAS system issues should be administered and/or discontinued, if any, to ameliorate the potential for coronavirus infection and/or the severity of coronavirus infection. Typical coronaviruses to be treated include SARS coronavirus, MERS coronavirus and/or Covid-19 coronavirus. Co-administration of anti-viral, quinoline-like and/or quinone-like drugs and ACE2 agonists are also disclosed.
    Type: Application
    Filed: April 9, 2021
    Publication date: January 4, 2024
    Inventors: Eric Snyder, Scott C. Snyder, Ryan Sprissler
  • Publication number: 20210338708
    Abstract: The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.
    Type: Application
    Filed: March 18, 2021
    Publication date: November 4, 2021
    Inventors: Donald Jeffrey KEYSER, Alvaro F. GUILLEM, Bhupinder SINGH, Richard A. ZAGER, Stacey RUIZ
  • Publication number: 20210236497
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: April 16, 2020
    Publication date: August 5, 2021
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • Publication number: 20210261644
    Abstract: Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 26, 2021
    Inventors: Zhiwei Chen, Kwok Yung Yuen, Honglin Chen, Yik Chun Wong, Li Liu
  • Publication number: 20210322390
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: June 30, 2021
    Publication date: October 21, 2021
    Inventors: Dror Ben-Asher, Reza Fathi
  • Publication number: 20230256087
    Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.
    Type: Application
    Filed: January 19, 2023
    Publication date: August 17, 2023
    Inventor: Jorge E. OSORIO
  • Publication number: 20230000845
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: August 31, 2022
    Publication date: January 5, 2023
    Inventors: Dror Ben-Asher, Reza Fathi, Mark Levitt, Ofra Barnett
  • Patent number: 12005114
    Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: June 11, 2024
    Assignee: VAXTHERA SAS
    Inventor: Jorge E. Osorio
  • Publication number: 20220378815
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: August 3, 2022
    Publication date: December 1, 2022
    Applicant: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Patent number: 11052073
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: July 6, 2021
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • Publication number: 20210299108
    Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: June 10, 2021
    Publication date: September 30, 2021
    Inventors: Dror Ben-Asher, Reza Fathi
  • Publication number: 20220184053
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 16, 2022
    Inventors: Dror Ben-Asher, Reza Fathi
  • Patent number: 11364227
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: June 21, 2022
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi
  • Publication number: 20220040354
    Abstract: Various embodiments are directed to a coronavirus air sanitization/isolation system with anti-virus curtain. The system may include a group of anti-virus strips with attached separation magnets coupled to an air inlet housing mounted above (e.g., in an attic ceiling) in an enclosed space. The anti-virus strips may be coated with a saline and soap solution that attracts airborne droplets contaminated with the coronavirus and dissolves a fatty layer of coronavirus cell membranes to prevent cell replication of the coronavirus, thereby destroying the coronavirus. The air inlet housing may include exhaust ventilation fans, salt filters, a wick saturated with the saline and soap solution, an electro-static air filter, and a distribution air duct. The fans may be utilized to circulate an airstream containing the coronavirus through the anti-virus strips, the filters, the saturated wick, and the distribution air duct to remove the coronavirus while protecting occupants with uncontaminated air.
    Type: Application
    Filed: August 3, 2021
    Publication date: February 10, 2022
    Inventor: Charles Magee
  • Publication number: 20230110899
    Abstract: The present invention provides for use of fenretinide, fenretinide analog or pharmaceutically acceptable salts for the preparation of medicaments useful for the treatment of SARS-coronavirus, ARDS and SARS-coronavirus associated pneumonia and hypoxemia. In addition, prophylaxis of SARS-coronavirus, ARDS and SARS-coronavirus associated pneumonia is also contemplated.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 13, 2023
    Inventors: Radu Pislariu, Irenej Kianicka, Danuta Radzioch, Larry Lands
  • Publication number: 20230117744
    Abstract: The present disclosure provides compositions, for example vaccine compositions comprising live, attenuated coronavirus. The disclosure also provides methods of using coronavirus vaccines, including methods of treating and/or preventing coronavirus infections, and provides methods of preparing coronavirus vaccines.
    Type: Application
    Filed: March 23, 2021
    Publication date: April 20, 2023
    Inventors: Susan Baker, Xufang Deng, Kelly Milton Lager, Kay Faaberg, Alexandra DeVries
Narrow Results

Filter by US Classification